Inspire Medical Systems Inc

Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inspire Medical Systems achieves first profitable quarter, eyes international growth

Inspire Medical Systems reported a strong performance in Q4 2022, achieving its first profitable quarter and significant revenue growth. The company's focus on enhancing patient outcomes, expanding internationally, and optimizing operational efficiency positions it for continued success.
While challenges with the supply chain were addressed, the company needs to remain vigilant in managing disruptions and addressing analyst concerns to ensure sustained growth. Opportunities in product demand, market expansion, and operational enhancements offer avenues for further development.
Overall, Inspire Medical Systems' strategic initiatives, strong financial performance, and commitment to innovation indicate a positive outlook for future growth and market expansion. The company's focus on driving utilization, improving patient outcomes, and maintaining operational efficiency bodes well for its long-term success.

Inspire Medical Systems Inc reports stellar Q1 performance and eyes global growth opportunities

Inspire Medical Systems Inc delivered robust financial results in Q1 2023, driven by revenue growth and international expansion.
The company's strategic focus on innovation, customer engagement, and therapy adoption positions it well for future success.
Challenges in competition, operational efficiency, and market dynamics require careful navigation, but opportunities for growth and innovation abound.
Overall, Inspire's performance reflects a company poised for continued expansion and impact in the medical technology sector.

Inspire Medical Systems reports robust Q2 growth and eyes global expansion

Inspire Medical Systems delivered strong financial performance in Q2, with revenue growth and margin improvement.
The company's strategic focus on expanding globally, enhancing operational efficiency, and product innovation positions it for future success.
While facing challenges in managing expenses and market mix, Inspire Medical Systems is well-positioned to capitalize on growth opportunities.
Overall, the company's performance, strengths, and strategic initiatives indicate a positive outlook for future growth and market expansion.

Inspire Medical Systems achieves record patient milestone and revenue growth

Inspire Medical Systems reported strong performance in Q3 2023, with notable revenue growth and patient milestones.
Despite challenges with prior authorizations and EU MDR approval delays, the company remains focused on growth and stakeholder value.
Opportunities for expansion with payers and new programs signal a positive outlook for future growth and market reach.
Efforts to streamline processes, educate centers, and drive efficiencies position the company for continued success in the sleep apnea treatment market.

Inspire Medical Systems posts robust Q4 results, eyes global expansion

Inspire Medical Systems reported strong Q4 performance, focusing on growth, profitability, and patient outcomes.
Challenges include market competition, revenue declines in certain regions, and securing reimbursements.
Opportunities lie in expanding utilization rates, market growth in Europe and Asia, and collaborations for increased patient flow.

Inspire Medical Systems Inc reports robust Q1 performance and growth outlook

Inspire Medical Systems Inc's Q1 2024 performance reflects strong revenue growth, improved net loss metrics, and a positive outlook for profitability and revenue expansion in 2024.
The company's strengths lie in its patient-centric approach, innovative product pipeline, and strategic growth initiatives, while challenges include financial performance, competitive landscape, and market penetration.
Opportunities abound in expanding patient qualification, market awareness, and operational efficiency, positioning Inspire for sustained growth and market leadership in the healthcare sector.

Inspire Medical Systems reports strong Q2 performance and growth outlook

Inspire Medical Systems demonstrated robust financial performance, marked by revenue growth and improved profitability.
Strategic initiatives to enhance patient experience and expand market reach position the company for sustained growth.
While facing challenges related to rising expenses, the company's focus on operational efficiency and growth opportunities remains strong.

Inspire Medical Systems reports strong Q3 earnings and growth outlook

Inspire Medical Systems Inc demonstrated robust financial performance in Q3 2024, with revenue and net income showing significant growth.
Despite challenges like revenue headwinds in Q4, the company's focus on innovation and capacity expansion presents growth opportunities.
The upcoming launch of the Inspire V system and efforts to streamline patient access highlight Inspire's commitment to driving future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bunzl PLC

INSP and BZLFY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 21, 2023.

Best Momentum Stocks to Buy for February 21st

Airbnb

Herbalife

INSP, ABNB and HLF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 17, 2023.

Best Momentum Stocks to Buy for February 17th

Kirin Holdings Co Ltd

Vertex Energy

KNBWY, INSP, HLF, VTNR and HBT have been added to the Zacks Rank #1 (Strong Buy) List on February 17, 2023.

New Strong Buy Stocks for February 17th

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Inspire Medical Systems, Inc. (NYSE: INSP) concerning the Company and its directors' and officers' possible violations of state laws.

Glancy Prongay & Murray LLP Announces Investigation of Inspire Medical Systems, Inc. (INSP)

Inspire is Wednesday's IBD Stock Of The Day. The sleep apnea expert reported massive sales growth, leading shares to break out.

INSP Stock Breaks Out On Massive Sales Growth

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the fourth quarter.

Inspire Medical (INSP) Q4 Earnings, Revenues Top Estimates

Inspire Medical Systems, Inc. (NYSE:INSP ) Q4 2022 Results Conference Call February 7, 2023 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Robbie Marcus - JPMorgan Adam Maeder - Piper Sandler Rich Newitter - Truist Larry Biegelsen - Wells Fargo John Block - Stifel Michael Polark - Wolfe Research Chris Pasquale - Nephron Research Matthew Mishan - KeyBanc Suraj Kalia - Oppenheimer Operator Good afternoon. My name is Josh, and I'll be your conference operator today.

Inspire Medical Systems, Inc. (INSP) Q4 2022 Earnings Call Transcript

Inspire (INSP) delivered earnings and revenue surprises of 118.52% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical Systems (INSP) Beats Q4 Earnings and Revenue Estimates

Inspire Reports First Profitable Quarter and Year-over-Year Revenue Growth of 76% in the Fourth Quarter Inspire Reports First Profitable Quarter and Year-over-Year Revenue Growth of 76% in the Fourth Quarter

Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance

Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Albemarle

Axsome Therapeutics

These three companies should deliver inflation-busting long-term growth.

The Ultimate Growth Stocks to Buy With $300 Right Now

Catalyst Pharmaceuticals

iShares Nasdaq Biotechnology ETF

Novocure

Revance Therapeutics

Teva Pharmaceutical

Vertex Pharmaceuticals

Zai Lab Ltd.

Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.

Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride

Market-makers then told us INSP stock price could likely grow +20% in 6 weeks, as it had 39 times in previous four years. Wrong: it only took 3 weeks. Now they're back with a calmer story of only +16% gain in 6 weeks, but point to twice as many gains of that size, anticipated in the last 4 years.

Inspire Medical Repeats Months Ago: Quick Cap-Gain Profit Likely

MINNEAPOLIS, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the fourth quarter and fiscal 2022 after the close of trading on Tuesday, February 7. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2022 Financial Results on February 7, 2023

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the quarter and full year ended December 31, 2022.

Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022

Incyte

Madrigal Pharmaceuticals

Schrodinger 

Veeva Systems

Verona Pharma

Viatris

With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.

Why These 7 Healthcare Stocks Could Soar in 2023

Genmab - ADR

Medpace Holdings

These leading biotech stocks have had a good quarter and some may have room to run, while for others it's time to ring the register. The post Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close appeared first on Investor's Business Daily.

Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close

MINNEAPOLIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at the Westin St. Francis Hotel in San Francisco, CA.

Inspire Medical Systems, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

Inspire Adopts SASB Reporting Standards Inspire Adopts SASB Reporting Standards

Inspire Medical Systems, Inc. Publishes Inaugural ESG Summary Report

Biogen

BioNTech SE

Eli Lilly

Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks.

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

MINNEAPOLIS, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at the Lotte New York Palace Hotel in New York, NY.

Inspire Medical Systems, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference

Inspire Medical Systems, Inc. (NYSE:INSP ) Q3 2022 Earnings Conference Call November 1, 2022 5:00 PM ET Company Participants Ezgi Yagci - IR Tim Herbert - President & CEO Rick Buchholz - CFO Conference Call Participants Travis Steed - Bank of America Jonathan Block - Stifel Robbie Marcus - JP Morgan Larry Biegelsen - Wells Fargo Adam Maeder - Piper Sandler Chris Pasquale - Nephron Research Rich Newitter - Truist Phil Coover - Goldman Sachs Suraj Kalia - Oppenheimer Operator Good afternoon. My name is Dalen, and I'll be your conference operator today.

Inspire Medical Systems, Inc. (INSP) Q3 2022 Earnings Call Transcript

Inspire (INSP) delivered earnings and revenue surprises of 20% and 14.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical Systems (INSP) Reports Q3 Loss, Tops Revenue Estimates

Inspire Reports Year-over-Year Revenue Growth of 77% in the Third Quarter Inspire Reports Year-over-Year Revenue Growth of 77% in the Third Quarter

Inspire Medical Systems, Inc. Announces Third Quarter 2022 Financial Results and Updates 2022 Outlook

A 3-5 month prospect from here of Inspire Medical Systems, Inc. share prices could reasonably range from a $166 low to a $210 high from its present price of $175, a +20.8% gain. 39 positions like today's in the past 5 years of 1042 market days produced average net gains at 23.4% each during 31 market days (6 weeks) or +450% CAGR.

News for Inspire Medical Systems Inc Stock (INSP)